1. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;
2. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain;
3. Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain;
4. Hospital Nostra Senyora de Meritxell, Escaldes-Engordany, Andorra;
5. Cytogenetic Laboratory and
6. Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute–Oncology Center, Warsaw, Poland;
7. Institute of Human Genetics, Ulm University Medical Center, Ulm University, Ulm, Germany;
8. Institute of Human Genetics, Christian Albrechts University Kiel/University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;
9. Institut de Pathologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;
10. Institute of Pathology and
11. Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany;
12. Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA;
13. Cleveland Clinic Foundation, Cleveland, OH;
14. Department of Pathology and Microbiology and
15. Division of Oncology and Hematology, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE;
16. Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada;
17. Oslo University Hospital, Oslo, Norway;
18. Department of Pathology, City of Hope National Medical Center, Duarte, CA;
19. VU University Medical Center, Amsterdam, The Netherlands;
20. Hospital Universitari de Bellvitge–Institut d’Investigació Biomédica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Spain;
21. Haematological Malignancy Diagnostic Service (HMDS) Laboratory, St. James’s Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom;
22. Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA;
23. Joint Barcelona Supercomputing Center (BSC)–Centre for Genomic Regulation (CRG)–Institute for Research in Biomedicine (IRB) Research Programme in Computational Biology, Barcelona, Spain;
24. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain;
25. Centre Nacional d’Anàlisi Genòmica (CNAG)–CRG, Barcelona, Spain;
26. Laboratori de Citogenètica Molecular, Servei de Patologia, Hospital del Mar, Barcelona, Spain;
27. Grup de Recerca Translacional en Neoplàsies Hematològiques, Cancer Research Programme, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM)–Hospital del Mar, Barcelona, Spain;
28. Hematopathology Section, Hospital Clínic de Barcelona, Barcelona, Spain;
29. Department of Clinical Pathology and
30. Dr Margarete “Fischer Bosch Institute” of Clinical Pharmacology, Robert Bosch Hospital, Stuttgart, Germany;
31. Institute of Pathology, Eberhard Karls University of Tübingen, Tübingen, Germany;
32. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and
33. Department of Anatomic Pathology, University of Barcelona, Barcelona, Spain